Worth reading
44Recurring
Scored from 1 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
0
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
13th Stock Acquisition Rights issued through a third-party allotment (with an exercise price adjustment clause)
発行・処分する株式数
Number of shares issued during the month: 0 shares (new shares: 0 shares; transferred treasury shares: 0 shares)
発行済株式総数
Exercise ratio subject to exercise restrictions: 0.00% (①/②)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
No exercises during the reporting month. Details of the adjustment clause: Not disclosed
Number of Stock Acquisition Rights
Total number issued: 140,000 warrants; number of unexercised warrants remaining as of the end of the month preceding the reporting month: 108,900; number of unexercised warrants remaining as of the end of the reporting month: 108,900
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing
Issued on 14 October 2025: Series 13 Stock Acquisition Rights (with exercise price adjustment clause), 140,000 warrants issued in total
| Item | Details |
|---|---|
| Type of issuance or disposal | 13th Stock Acquisition Rights issued through a third-party allotment (with an exercise price adjustment clause) |
| Number of shares to be issued or disposed of | Number of shares issued during the month: 0 shares (new shares: 0 shares; transferred treasury shares: 0 shares) |
| Dilution Rate | Exercise ratio subject to exercise restrictions: 0.00% (①/②) |
| Total number of issued shares | As of the end of the month preceding the reporting month: 49,248,593 shares → Not disclosed |
| Exercise price | No exercises during the reporting month. Details of the adjustment clause: Not disclosed |
| Number of Stock Acquisition Rights | Total number issued: 140,000 warrants; number of unexercised warrants remaining as of the end of the month preceding the reporting month: 108,900; number of unexercised warrants remaining as of the end of the reporting month: 108,900 |
| Procedures under the Corporate Code of Conduct | The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations |
| Most recent equity financing | Issued on 14 October 2025: Series 13 Stock Acquisition Rights (with exercise price adjustment clause), 140,000 warrants issued in total |
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.No reason was given by the company.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.